<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2018.74014</article-id><article-id pub-id-type="publisher-id">PI-25794</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20180400000_28846048.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  新型调血脂药物的应用研究进展
  Research Progress of Application of Novel Li-pid-Regulating Drugs
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>商</surname><given-names>博</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>隋</surname><given-names>常琪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>牧</surname><given-names>童</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>内蒙古医科大学药学院，内蒙古 呼和浩特</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2018</year></pub-date><volume>07</volume><issue>04</issue><fpage>74</fpage><lpage>78</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   血脂异常被世界医学界公认是导致动脉粥样硬化和心脑血管各种疾病的“元凶”。目前临床上的用于治疗血脂异常的药物主要包括他汀类、贝特类、烟酸类及胆汁酸螯合剂等。近年来，随着胆固醇代谢的一些新靶点的发现，也催生出很多有新作用机制的药物走向临床试验或上市，本文将介绍近年来新型调血脂药物的应用研究进展。 Dyslipidemia is recognized by the world medical community as the “culprit” that causes atherosclerosis and various cardiovascular and cerebrovascular diseases. Current clinical drugs for the treatment of dyslipidemia include statins, fibrates, nicotinic acid, and bile acid sequestrants. In recent years, with the discovery of some new targets for cholesterol metabolism, many drugs with new mechanisms have also been developed for clinical trials or marketing. This article will introduce the recent advances in the application of novel lipid regulating drugs. 
  
 
</p></abstract><kwd-group><kwd>调血脂药，前蛋白转化酶枯草溶菌素-9 (PSCK-9)抑制剂，胆固醇吸收抑制剂，ω-3脂肪酸，微粒体甘油三脂转运蛋白(MTP)抑制剂, Lipid-Regulating Drugs</kwd><kwd> Proprotein Convertase Subtilisinkexin Type 9 (PSCK-9) Inhibitor</kwd><kwd> Cholesterol Absorption Inhibitor</kwd><kwd> Omega-3 Fatty Acids</kwd><kwd> Microsomal Triglyceride Transfer Protein (MTP) Inhibitor</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>新型调血脂药物的应用研究进展<sup> </sup></title><p>商博，隋常琪，牧童，杨慧<sup>*</sup></p><p>内蒙古医科大学药学院，内蒙古 呼和浩特</p><disp-formula id="hanspub.25794-formula20"><graphic xlink:href="//html.hanspub.org/file/2-1710146x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年6月25日；录用日期：2018年7月3日；发布日期：2018年7月10日</p><disp-formula id="hanspub.25794-formula21"><graphic xlink:href="//html.hanspub.org/file/2-1710146x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>血脂异常被世界医学界公认是导致动脉粥样硬化和心脑血管各种疾病的“元凶”。目前临床上的用于治疗血脂异常的药物主要包括他汀类、贝特类、烟酸类及胆汁酸螯合剂等。近年来，随着胆固醇代谢的一些新靶点的发现，也催生出很多有新作用机制的药物走向临床试验或上市，本文将介绍近年来新型调血脂药物的应用研究进展。</p><p>关键词 :调血脂药，前蛋白转化酶枯草溶菌素-9 (PSCK-9)抑制剂，胆固醇吸收抑制剂，ω-3脂肪酸，微粒体甘油三脂转运蛋白(MTP)抑制剂</p><disp-formula id="hanspub.25794-formula22"><graphic xlink:href="//html.hanspub.org/file/2-1710146x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1710146x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-1710146x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>随着人民的生活水平不断提高，居民整体健康水平的现况却不容乐观，心血管疾病已经成为威胁人们生命健康的“头号杀手”。《中国心血管病报告(2017)》指出，我国心血管病的患病率和死亡率仍然处于持续上升阶段，根据往年数据推算，目前国内心血管病患病人数高达2.9亿 [<xref ref-type="bibr" rid="hanspub.25794-ref1">1</xref>]。心血管病死亡率近年来始终居高不下，高于肿瘤及其他疾病 [<xref ref-type="bibr" rid="hanspub.25794-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.25794-ref3">3</xref>] ，占居民死亡构成45%以上。而脂质异常是导致心血管疾病的重要原因之一。</p><p>他汀类作为调血脂药的一线药物在临床上广泛应用，该类药物疗效确切，效果显著，但副作用也同样给医生和患者带来了一定的困扰。贝特类，烟酸类和胆酸螯合剂在临床上应用于无法耐受他汀类药物的其他患者。近年来，新型调血脂药前蛋白转化酶枯草溶菌素-9 (PSCK-9)抑制剂，胆固醇吸收抑制剂及微粒体甘油三脂转运蛋白(MTP)抑制剂在治疗血脂异常的应用开始引起人们的关注，本文将综述近年来新型调血脂药物应用研究进展。</p></sec><sec id="s4"><title>2. 降低胆固醇为主的药物</title><sec id="s4_1"><title>2.1. 依折麦布</title><p>依折麦布于2002年在美国获批上市。到目前为止，该药是唯一一个上市的胆固醇吸收抑制剂。NPC1L1是一种负责转运肠道中的胆固醇进入细胞的跨膜蛋白，该药作用于小肠粘膜上的NPC1L1转运蛋白，选择性抑制食物和胆汁中的胆固醇跨小肠转运。减少总胆固醇储存，增加肝脏低密度脂蛋白受体的合成，并且降低低密度脂蛋白水平。非饮食性高胆固醇血症患者不建议使用该种药物。</p><p>依折麦布通常用于治疗降低LDL-C水平尚未达到治疗目标或不耐受他汀类药物的患者。在心脏和肾脏保护(SHARP)试验中研究了依折麦布与辛伐他汀联合应用的疗效，该试验比较了依折麦布10 mg加辛伐他汀20 mg/天与安慰剂组治疗中重度慢性肾病患者的疗效 [<xref ref-type="bibr" rid="hanspub.25794-ref4">4</xref>]。接受依折麦布加辛伐他汀组的患者发生非致命性心肌梗死或冠状动脉死亡，非出血性中风或任何动脉血运重建术的主要复合终点的发生率显著降低。辛伐他汀与更有效的降脂方案即辛伐他汀加依折麦布合用提供了依折麦布的有效性和安全性作为他汀类药物治疗的辅助药物的证据。依折麦布联合他汀类药物对于不耐受中高量他汀类的患者是一种不错的选择。</p><p>目前依折麦布临床上主要用于治疗高胆固醇血症，纯合子家族性高胆固醇血症和纯合子谷甾醇血症，副作用较小，肝肾功能损害患者都可以服用。仅有小部分患者可能会出现胃肠道的不良反应，如腹痛腹泻等症状。</p></sec><sec id="s4_2"><title>2.2. 前蛋白转化酶枯草溶菌素-9 (PSCK-9)抑制剂</title><p>新型的蛋白酶前蛋白转化酶枯草溶菌素-9 (PSCK-9)抑制剂(最初称为神经凋亡调节转化酶-1)首先由Seidah等人提出 [<xref ref-type="bibr" rid="hanspub.25794-ref5">5</xref>]。该类药物结合PCSK9并抑制PCSK9与低密度脂蛋白受体(LDLR)的结合，从而阻止PCSK9介导的低密度脂蛋白受体降解。</p><p>Stein等人报道了静脉内或皮下注射alirocumab的三期I期试验的结果 [<xref ref-type="bibr" rid="hanspub.25794-ref6">6</xref>]。一项研究是在血清LDL-C浓度 &gt; 100 mg/dl的健康志愿者中进行的，而另外两项研究是在用阿托伐他汀治疗杂合子家族性高胆固醇血症(FH)或非FH患者中进行的。PCSK9抑制剂耐受良好，并与LDL-C，总胆固醇，非HDL-C，apoB和脂蛋白(a) (Lp(a))水平的降低均有关。</p><p>在没有服用其他降脂药的高胆固醇血症患者中应用依伏库单抗的研究显示，所有剂量组中LDL-C显着降低约40%~50% [<xref ref-type="bibr" rid="hanspub.25794-ref7">7</xref>]。另一项II期临床试验涉及使用或不使用依折麦布的他汀治疗的高胆固醇血症患者，每2周接受依伏库单抗组的LDL-C降低42%~66%，每4周一次接受依伏库单抗组降低42%~50% [<xref ref-type="bibr" rid="hanspub.25794-ref8">8</xref>]。在该项研究中，该药物的耐受性一般都很好。随着越来越多令人欣喜的临床试验结果的出现，阿利库单抗和依伏库单抗于2015年在美国获批上市。</p><p>PCSK-9抑制剂作为新型调血脂药物，其降低胆固醇和心血管病事件作用得到了众多临床试验证实。但是，PCSK9还有一些对神经系统和内分泌系统的影响值得引起科研人员的重视。其参与肝脏再生 [<xref ref-type="bibr" rid="hanspub.25794-ref5">5</xref>] 、神经细胞凋亡 [<xref ref-type="bibr" rid="hanspub.25794-ref9">9</xref>] 的调节，并有可能导致胰岛细胞功能异常和糖耐量受损 [<xref ref-type="bibr" rid="hanspub.25794-ref10">10</xref>] ，因此，PCSK9抑制剂是否会对内分泌系统、循环系统和中枢神经系统产生不良影响仍有待观察。而且目前PCSK-9抑制剂仅能通过皮下注射用药，存在注射部位红斑、瘙痒、肿胀、疼痛等不良反应，加之昂贵的价格可能导致患者依从性下降。</p></sec><sec id="s4_3"><title>2.3. 微粒体甘油三脂转运蛋白(MTP)抑制剂</title><p>MTP抑制剂通过减少肝脏VLDL和小肠乳糜微粒的合成和分泌，从而使血液VLDL、TG和LDL-C水平的水平降低 [<xref ref-type="bibr" rid="hanspub.25794-ref11">11</xref>]。在临床前的研究中发现影响MTP活性的药物使甘油三酯和胆固醇水平的显着降低。对MTP抑制剂(如英普他派)的早期研究揭示了它们降低LDL-C水平的能力。然而，由于担心该类药物与胃肠副作用和肝脏脂肪堆积有关，大多数药物的进一步开发已经停止。Lomitapide成为唯一一个超过II期临床试验开发的MTP抑制剂 [<xref ref-type="bibr" rid="hanspub.25794-ref12">12</xref>]。该药在纯合子家族性高胆固醇血症(hoFH)动物模型中显着降低LDL-C水平 [<xref ref-type="bibr" rid="hanspub.25794-ref13">13</xref>]。在临床情况下，该药物单独或联合依折麦布时被证明可有效减少hoFH39患者 [<xref ref-type="bibr" rid="hanspub.25794-ref14">14</xref>] 和中度高胆固醇血症患者的血浆脂质(单独降低LDL-C和apoB分别为30%和24%，合用依折麦布降低LDL-C为46%) [<xref ref-type="bibr" rid="hanspub.25794-ref15">15</xref>]。然而，在这些研究中发现了胃肠副作用，轻微转氨酶水平的升高和肝脂肪的增加。尽管有这些副作用，洛美他派于2012年12月被批准用于治疗hoFH。</p><p>如上所述，在临床试验中给予MTP抑制剂会导致肝转氨酶水平不可接受地升高和肝脂肪分解增加。由于这些原因，除了已被批准用来治疗hoFH洛美他派外，基本上停止了MTP抑制剂的临床开发。</p></sec></sec><sec id="s5"><title>3. 降TG为主的药物</title>ω-3脂肪酸<p>尽管ω-3脂肪酸(二十碳五烯酸-二十二碳六烯酸[EPA-DHA])不能降低LDL的水平，但膳食补充鱼油或使用ω-3酸乙酯在高危心血管疾病的人群甚至甘油三酯升高的人群中的使用已经比较普遍。尽管ω-3脂肪酸对于调控胆固醇的作用机制尚不明确，但目前清楚的是可以降低VLDL-C和甘油三脂的合成，也可以增加甘油三脂的清除率 [<xref ref-type="bibr" rid="hanspub.25794-ref16">16</xref>]。当和他汀类药物联用时，ω-3酸乙酯分别平均降低总胆固醇和甘油三酯水平5%和30%。分别增加LDL和HDL的水平1%和3% [<xref ref-type="bibr" rid="hanspub.25794-ref17">17</xref>]。令人感兴趣的是，有证据表明，最近批准在美国使用的纯化EPA (二十碳五烯乙基)不会增加LDL-C，并且实际上降低了这些水平 [<xref ref-type="bibr" rid="hanspub.25794-ref18">18</xref>]。</p><p>总体而言，临床试验表明，ω-3酸乙酯是安全的，并可能降低某些人群心血管事件的风险。额外的临床试验有必要评估纯的EPA和EPA-DHA对心血管预后可能存在的差异。</p></sec><sec id="s6"><title>4. 升高HDL-C为主的药物</title>胆固醇酯转运蛋白(CETP)抑制剂<p>流行病学研究证明，低密度脂蛋白(LDL)和高密度脂蛋白(HDL)是调整心血管事件的独立因子。大量的流行病学资料证明血清高密度脂蛋白胆固醇水平与心血管事件呈现明显的负相关关系 [<xref ref-type="bibr" rid="hanspub.25794-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.25794-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.25794-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.25794-ref22">22</xref>]。胆固醇酯转运蛋白(CETP)是胆固醇酯逆转运过程中的关键蛋白，促进HDL-C向LDL-C和极低密度脂蛋白(VLDL-C)转运，从而降低体内HDL-C水平，升高LDL-C水平，诱发心血管疾病的发生。CETP抑制剂抑制脂蛋白之间的脂质交换，从而达到升高HDL-C，降低LDL-C的目的 [<xref ref-type="bibr" rid="hanspub.25794-ref23">23</xref>]。</p><p>CETP抑制剂torcetrapib (托塞匹布)和dalcetrapib (达塞曲匹)的相关临床研究显示，虽然上述两种药物都可以升高HDL-C，但是却不能降低心血管风险 [<xref ref-type="bibr" rid="hanspub.25794-ref24">24</xref>]。2006年，torcetrapib最终因为其安全问题而宣告停止研发，5年后罗氏公司的也因为类似的原因停止了dalcetrapib的研发工作。ACCELERATE研究显示evacetrapib (暂无中文译文)同样不能降低心血管事件发生风险 [<xref ref-type="bibr" rid="hanspub.25794-ref25">25</xref>] ，礼来公司于2015年宣布停止该药的研发工作。而此时默沙东却知难而进，宣布将开展其CETP新药anacetrapib的临床三期研究。</p><p>虽然CETP抑制剂的研发工作坎坷不断，但CETP抑制剂的高选择性一直是人们关注的热点，随着研发人员对CETP结构和作用机制的研究越来越深入，相信会有疗效更优和安全性更好药物开发出来。</p></sec><sec id="s7"><title>5. 总结</title><p>他汀类药物是降脂治疗的基石，在过去的30年中，该类药物已被证明是安全有效的药物。最近，随着新的基因技术和转化方法的发展，创新疗法的开发已经取得了相当大的进展。事实上，新药的开发给降脂治疗和降低心血管风险发生率带来了很大的希望。然而，从安全性的角度考虑，很多新药的发展都受到了限制，比如MTP抑制剂。因此，接下来的研究应该进一步探索这些药物的安全性。这些新兴疗法的试验目前正在进行中，在未来几年预计会在脂质调节领域取得惊人的进展。</p></sec><sec id="s8"><title>文章引用</title><p>商 博,隋常琪,牧 童,杨 慧. 新型调血脂药物的应用研究进展 Research Progress of Application of Novel Li-pid-Regulating Drugs[J]. 药物资讯, 2018, 07(04): 74-78. https://doi.org/10.12677/PI.2018.74014</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.25794-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">陈伟伟, 高润霖, 刘力生. 《中国心血管病报告(2017)》概要[J]. 中国循环杂志, 2018, 33(1): 1-8.</mixed-citation></ref><ref id="hanspub.25794-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">国家卫生和计划生育委员会. 中国卫生和计划生育统计年鉴2016 [M]. 北京: 中国协和医科大学出版社, 2016.</mixed-citation></ref><ref id="hanspub.25794-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中华人民共和国卫生部. 中国卫生统计年鉴2009~2012 [M]. 北京: 中国协和医科大学出版社, 2009-2012.</mixed-citation></ref><ref id="hanspub.25794-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Colin, B., Landray, M.J., Christina, R., et al. (2011) The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease (Study of Heart and Renal Protection): A Randomised Placebo-Controlled Trial. Lancet, 377, 2181-2192. &lt;br&gt;https://doi.org/10.1016/S0140-6736(11)60739-3</mixed-citation></ref><ref id="hanspub.25794-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Seidah, N.G., Benjannet, S., Wickham, L., et al. (2003) The Secretory Pro-protein Convertase Neural Apoptosis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation. Proceed-ings of the National Academy of Sciences of the United States of America, 100, 928-933. &lt;br&gt;https://doi.org/10.1073/pnas.0335507100</mixed-citation></ref><ref id="hanspub.25794-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Stein, E.A., Mellis, S., Yancopoulos, G.D., et al. (2012) Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. The New England Journal of Medicine, 366, 1108-1118. &lt;br&gt;https://doi.org/10.1056/NEJMoa1105803</mixed-citation></ref><ref id="hanspub.25794-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Koren, M.J., Scot,t R., Kim, J.B., et al. (2012) Efficacy, Safety, and Tolerability of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 as Monotherapy in Patients with Hypercholesterolaemia (MENDEL): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study. Lancet, 380, 1995-2006.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(12)61771-1</mixed-citation></ref><ref id="hanspub.25794-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Giugliano, R.P., Desai, N.R., Kohli, P., et al. (2012) Efficacy, Safety, and Tolerability of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 in Combination with a Statin in Patients with Hypercholesterolaemia (LAPLACE-TIMI 57): A Randomised, Placebo-Controlled, Dose-Ranging, Phase 2 Study. Lancet, 380, 2007-2017.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(12)61770-X</mixed-citation></ref><ref id="hanspub.25794-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Q., Tang, Z.H., Peng, J., et al. (2014) The Dual Behavior of PCSK9 in the Regulation of Apoptosis Is Crucial in Alzheimer’s Disease Progression (Review). Biomedical Reports, 2, 167-171. &lt;br&gt;https://doi.org/10.3892/br.2013.213</mixed-citation></ref><ref id="hanspub.25794-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mbikay, M., Sirois, F., Mayne, J., et al. (2010) PCSK9-Deficient Mice Exhibit Impaired Glucose Tolerance and Pancreatic Islet Abnormalities. FEBS Letters, 584, 701-706. &lt;br&gt;https://doi.org/10.1016/j.febslet.2009.12.018</mixed-citation></ref><ref id="hanspub.25794-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">GouniBerthold, I. and Berthold, H.K. (2015) Mipomersen and Lomitapide: Two New Drugs for the Treatment of Homozygous Familial Hypercholesterolemia. Atherosclerosis Supplements, 18, 28-34.  
&lt;br&gt;https://doi.org/10.1016/j.atherosclerosissup.2015.02.005</mixed-citation></ref><ref id="hanspub.25794-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cuchel, M. and Rader, D.J. (2013) Microsomal Transfer Protein Inhibition in Humans. Current Opinion in Lipidology, 24, 246-250. &lt;br&gt;https://doi.org/10.1097/MOL.0b013e32836139df</mixed-citation></ref><ref id="hanspub.25794-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wetterau, J.R., Gregg, R.E., Harrity, T.W., et al. (1998) An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits. Science, 282, 751-754. &lt;br&gt;https://doi.org/10.1126/science.282.5389.751</mixed-citation></ref><ref id="hanspub.25794-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Cuchel, M., Bloedon, L.T., Szapary, P.O., et al. (2007) Inhibition of Micro-somal Triglyceride Transfer Protein in Familial Hypercholesterolemia. The New England Journal of Medicine, 356, 148-156.  
&lt;br&gt;https://doi.org/10.1056/NEJMoa061189</mixed-citation></ref><ref id="hanspub.25794-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Samaha, F.F., McKenney, J., Bloedon, L.T., et al. (2008) Inhibition of Microsomal Triglyceride Transfer Protein Alone or with Ezetimibe in Patients with Moderate Hypercholesterolemia. Nature Clinical Practice Car-diovascular Medicine, 5, 497-505. &lt;br&gt;https://doi.org/10.1038/ncpcardio1250</mixed-citation></ref><ref id="hanspub.25794-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Harris, W.S., Miller, M., Tighe, A.P., et al. (2008) Omega-3 Fatty Acids and Coronary Heart Disease Risk: Clinical and Mechanistic Perspectives. Atherosclerosis, 197, 12-24. &lt;br&gt;https://doi.org/10.1016/j.atherosclerosis.2007.11.008</mixed-citation></ref><ref id="hanspub.25794-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Davidson, M.H., Stein, E.A., Bays, H.E., et al. (2007) Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4 g/d to Simvastatin 40 mg/d in Hypertriglyceridemic Patients: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study. Clinical Therapeutics, 29, 1354-1367. &lt;br&gt;https://doi.org/10.1016/j.clinthera.2007.07.018</mixed-citation></ref><ref id="hanspub.25794-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ballantyne, C.M., Bays, H.E., Kastelein, J.J., et al. (2012) Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients with Persistent High Triglycerides (from the ANCHOR Study). American Journal of Cardiology, 110, 984-992. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2012.05.031</mixed-citation></ref><ref id="hanspub.25794-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Robins, S.J., Collins, D., Wittes, J.T., et al. (2001) Relation of Gemfibrozil Treatment and Lipid Levels with Major Coronary Events: VA-HIT: A Randomized Controlled Trial. JAMA, 285, 1585-1591.  
&lt;br&gt;https://doi.org/10.1001/jama.285.12.1585</mixed-citation></ref><ref id="hanspub.25794-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Barter, P.J. and Kastelein, J.J. (2006) Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease. Journal of the American College of Cardiology, 47, 492-499.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2005.09.042</mixed-citation></ref><ref id="hanspub.25794-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Brown, B.G., Zhao, X.Q., Chait, A., et al. (2001) Simvastatin and Niacin, Anti-oxidant Vitamins, or the Combination for the Prevention of Coronary Disease. The New England Journal of Medicine, 345, 1583-1592.  
&lt;br&gt;https://doi.org/10.1056/NEJMoa011090</mixed-citation></ref><ref id="hanspub.25794-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Forrester, J.S. and Shah, P.K. (2006) Emerging Strategies for Increasing High-Density Lipoprotein. American Journal of Cardiology, 98, 1542-1549. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2006.06.059</mixed-citation></ref><ref id="hanspub.25794-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Eyvazian, V.A. and Frishman, W.H. (2017) Evacetrapib: Another CETP In-hibitor for Dyslipidemia with No Clinical Benefit. Cardiology in Review, 25, 43-52. &lt;br&gt;https://doi.org/10.1097/CRD.0000000000000137</mixed-citation></ref><ref id="hanspub.25794-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Brinton, E.A., Kher, U., Shah, S., et al. (2015) Effects of Anacetrapib on Plasma Lipids in Specific Patient Subgroups in the Define (Determining the Efficacy and Tolerability of CETP Inhibition with Anace-trapib) Trial. Journal of Clinical Lipidology, 9, 65-71. &lt;br&gt;https://doi.org/10.1016/j.jacl.2014.10.005</mixed-citation></ref><ref id="hanspub.25794-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Hovingh, G.K., Kastelein, J.J., Van Deventer, S.J., et al. (2015) Cholesterolester Transfer Protein Inhibition by TA-8995 in Patients with Mild Dyslipidemia (TULIP): A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial. The Lancet, 386, 452-460. &lt;br&gt;https://doi.org/10.1016/S0140-6736(15)60158-1</mixed-citation></ref></ref-list></back></article>